P-1899. Improvement in Provider Experiences from Baseline to Month 12 with Integrating Cabotegravir Long-Acting (CAB LA) for PrEP into Care in an Implementation Science Trial (PILLAR)
Taimur Khan(Fenway Health), Nanlesta Pilgrim, William R. Lenderking(Ithaka Harbors), N Jain(GlaxoSmithKline (United States)), Annemiek de Ruiter(ViiV Healthcare (Spain)), Nicola Barnes(University of Portsmouth), Lisa Petty, Heidi Swygard, Jonathan M. L. White(Université Libre de Bruxelles), Bo Li(North University of China), Maggie Czarnogorski, Todd McKeon, Katherine Nelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Acquadro(Ithaka Harbors), Leida Mercado(Valley Baptist Medical Center)
Cited by 0
Related Papers
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research
|Quality of Life Research|2013|855
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen
|The Lancet|1996|631